Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$18.56 USD
+0.10 (0.54%)
Updated May 31, 2024 04:00 PM ET
After-Market: $18.59 +0.03 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Denali Therapeutics Inc. [DNLI]
Reports for Purchase
Showing records 81 - 100 ( 184 total )
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Safety and Lysosomal Biomarker Data Important for the Success of DNL593?s Phase 1/2 Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Transport Vehicle Efforts Trucking Along - More Visibility Into DNL919 in 2H22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
All You Wanted to Know About TREM2 But Were Afraid to Ask-Hangover From Barcelona
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Bird''s Eye View of Disease-Modifying Targets of Parkinson''s Disease-AD/PD 2022 Live from Barcelona
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Considerations on the Phase 1b Study of DNL343 Set to Read Out in Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Durable Biomarker Data and Tolerable SafetyProfile of DNL310 Bode Well For the TV Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
DNL310 Continues To Show Durability - On To Phase 2/3 Study
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Reorienting Our Views on Hunter Syndrome Program and Broader Pipeline Implications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Microglia and Neurodegeneration, Denali?s Next Focus; Reit Buy and $105 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A